Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV

Allogene Overland Biopharm, the joint venture David Chang and Ed Zhang set up to turbocharge the development of off-the-shelf CAR-T therapies in China, has locked in its first CEO.

Shuyuan Yao joins from WuXi Advanced Therapies, the cell and gene therapy-focused arm of the sprawling contract testing, development and manufacturing...

Click to view original post